Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Risk of COVID-19 Reinfection and Vaccine Breakthrough Infection, Madera County, California, 2021

Minhphuong Nguyen, Eric Paul, Paul K. Mills, Simon Paul
doi: https://doi.org/10.1101/2022.01.22.22269105
Minhphuong Nguyen
1Madera County Department of Public Health, Madera, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Paul
2California Institute of Technology, Pasadena, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul K. Mills
3UCSF Fresno Department of Internal Medicine, Fresno, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Paul
1Madera County Department of Public Health, Madera, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: simon.paul@maderacounty.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The probability of either testing COVID-19 positive or dying for three cohorts in Madera County, California in 2021 was compared. These cohorts included 1. those unvaccinated, 2. those vaccinated and 3. persons with a previous COVID-19 infection. The three groups were made generally comparable by matching on age, gender, postal zip code of residence, and the date of either COVID-19 infection or of vaccination.

The hazard ratio (HR) for death (from all causes) after COVID-19 infection vs. vaccination was 11.7 (95% CI 5.91-23.1, p<0.05). The HR for testing positive for COVID-19 >14 days after initial COVID-19 infection or after completing primary COVID-19 vaccination was 1.98 (95% CI 1.53-2.58 p<0.001). As the majority of positive COVID-19 tests in the post COVID-19 cohort occurred within 90 days of the initial infection, and as these early positives may not represent a new infection, we also compared rates of testing COVID-19 positive ≥ 90 days after initial infection or vaccination. After removing these early positive COVID-19 tests that occurred between days 14-90, the HR ratio for testing COVID-19 positive is now lower for the post COVID-19 cohort compared with the vaccinated cohort. The risk for having a positive COVID-19 test occurring 90 days after an initial COVID-19 infection or after vaccination was 0.54 (95% CI 0.33-0.87, p<0.05) for the post COVID-19 group vs Vaccinated group.

Thus the risk for testing COVID-19 positive was higher in the first 90 days after COVID-19 infection compared to those vaccinated. However, from 90 to 300 days after COVID-19 infection, the post COVID-19 infection cohort had a lower risk of testing COVID-19 positive than those fully vaccinated.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was reviewed by the County of Fresno, Department of Public Health Institutional Review Board, and was approved on January 20, 2022.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 23, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Risk of COVID-19 Reinfection and Vaccine Breakthrough Infection, Madera County, California, 2021
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Risk of COVID-19 Reinfection and Vaccine Breakthrough Infection, Madera County, California, 2021
Minhphuong Nguyen, Eric Paul, Paul K. Mills, Simon Paul
medRxiv 2022.01.22.22269105; doi: https://doi.org/10.1101/2022.01.22.22269105
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Risk of COVID-19 Reinfection and Vaccine Breakthrough Infection, Madera County, California, 2021
Minhphuong Nguyen, Eric Paul, Paul K. Mills, Simon Paul
medRxiv 2022.01.22.22269105; doi: https://doi.org/10.1101/2022.01.22.22269105

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (162)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (863)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8571)
  • Forensic Medicine (4)
  • Gastroenterology (388)
  • Genetic and Genomic Medicine (1759)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1249)
  • Health Policy (622)
  • Health Systems and Quality Improvement (468)
  • Hematology (196)
  • HIV/AIDS (378)
  • Infectious Diseases (except HIV/AIDS) (10318)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (213)
  • Neurology (1682)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (328)
  • Occupational and Environmental Health (451)
  • Oncology (930)
  • Ophthalmology (264)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (538)
  • Pharmacology and Therapeutics (254)
  • Primary Care Research (209)
  • Psychiatry and Clinical Psychology (1775)
  • Public and Global Health (3853)
  • Radiology and Imaging (626)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (521)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)